Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > REGULATORY
REGULATORY
- Nakajima of HPB Calls on Kampo Association to Collect Data, Make Case for Favorable Re-Pricing
May 30, 2012
- MHLW Adds 8 APIs/10 Products Including Xalkori to NHI Price List
May 30, 2012
- MHLW Sets Up Office for Promotion of Medical Innovation to Realize New 5-Year Strategy
May 29, 2012
- MHLW Selects 5 Additional Clinical Research Core Hospitals
May 29, 2012
- AZ, Government Not Accountable in Iressa Appeal, Osaka High Court
May 29, 2012
- Chicken Pox, Mumps, and Adult Pneumococcal Vaccines to Be Added to Routine Vaccination Programs in FY2014 “at Earliest”: Dr Niki of DPJ
May 28, 2012
- CSIMC Expert Subcommittee Holds 1st Meeting on Cost-Effective Assessment; Members Urge Caution
May 25, 2012
- CSIMC Approves Listing for 8 APIs/10 Products; Peak Sales of Xalkori Expected to Reach 11.2 Billion Yen
May 25, 2012
- DPJ’s PAL Subcommittee Calls for Mandatory Submission of Package Inserts
May 24, 2012
- DPJ’s Committee Prepares Submission of Lawmaker-Initiated Bill to Create Third-Party Organization
May 24, 2012
- CSIMC Recommends NHI Price Listing for 8 APIs/10 Products Including Xalkori, Poteligeo
May 24, 2012
- Working Group to Set Specific Targets for 5-Year Clinical Research/Trial Activation Plan
May 22, 2012
- 1st Committee to Discuss 5 Items Including Add’l Indication of Fibromyalgia for Lyrica on June 1
May 22, 2012
- Gov’t to Form 3 Strategic Councils for Science & Technology Policy, with Its 1st Meeting for Medical Care on May 25
May 22, 2012
- 2nd Committee on New Drugs to Discuss Approval for 4 Items Including Pfizer Japan’s RCC Treatment Axitinib
May 21, 2012
- MHLW, Daiichi Sankyo Call for Proper Use of Denosumab after 3 Deaths in US
May 21, 2012
- DPJ Committee Approves Proposal to Reform Preventive Vaccination System
May 18, 2012
- DPJ Subcommittee Proposes Inclusion of 3 Subsidized Vaccines in Regular Vaccination Programs
May 16, 2012
- Gov’t to Begin Operating “Drug Discovery Network” This FY with Initial Focus on Seeds for Anticancer Agents
May 14, 2012
- DPJ’s PAL Subcommittee Calls for Establishment of Third-Party Organization within MHLW
May 11, 2012
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…